The 5th Annual Tumor Models Boston continues to showcase the latest advancements in the application of preclinical models to enhance the translation of cancer therapies from animal to patient.
Learn how the industry have been selecting & characterizing in vitro models, ex vivo assays, syngeneic models, PDX, humanized mice models to optimize their application in preclinical and translational studies for targeted therapies, cancer immunotherapies and combination therapies.
Uncover the valuable clinical lessons that are helping to transform preclinical research through reverse translation and to extract more value from preclinical models to enhance preclinical and translational decision making into the clinic.
Tumor Models Boston 2017 will address the preclinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between preclinical and clinical studies.
Discover lessons from the clinic to progress future cancer treatments into the clinic more effectively and faster.
“This was a nice meeting with a good sized group of participants that made it easy to choose to both sit back and soak it all in or to meet one-on-one for in-depth discussions”
-Past Attendee of Tumor Models Series, Agilux Laboratories